Fresenius Kabi to acquire Rx and OTC company Akorn for $4.7bn; deal terminated
- Medical Devices
- Generic Drugs
- OTC, Consumer
- Radiopharmaceuticals, Contrast Agents
- Specialty Pharmaceuticals
- Payment Includes Cash
- Full Acquisition
- Includes Contract
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.